What is the current stock price of Geron Corporation (GERN)?

As of the latest market data, Geron Corporation (GERN) is trading at $1.26. The stock has seen a loss of -1.56% today.

Does Geron Corporation (GERN) pay a dividend?

Based on current data, Geron Corporation does not have a confirmed active dividend policy.

What is the market cap of Geron Corporation?

The current market capitalization of Geron Corporation (GERN) is approximately unavailable.

GERN

Geron Corporation·Healthcare

1.26

1.563%(−0.02)

Close Price

1.30

3.175%(+0.04)

Pre-Market

Last Updated: — ET

52W L: $1.0452W H: $2.01

GERN NEWS

zacks.com

May 19

Geron (GERN) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

globenewswire.com

May 18

Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective May 15, 2026, it granted stock options to purchase an aggregate of 333,750 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.

seekingalpha.com

May 12

Geron Corporation (GERN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

globenewswire.com

May 12

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population Additional presentations at EHA 2026 and ASCO 2026 include abstracts related to ongoing myelofibrosis and AML clinical programs FOSTER CITY, Calif.

globenewswire.com

May 12

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Investigator-sponsored study, conducted at the Moffitt Cancer Center, demonstrates safety and efficacy consistent with the Phase 3 IMerge trial in a broader patient population

seekingalpha.com

May 6

Geron Corporation (GERN) Q1 2026 Earnings Call Transcript

Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Sector

Healthcare

Industry

Biotechnology

Employees

229

IPO Date

1996-07-31

Beta

0.68

Websitewww.geron.com↗